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Background: Advanced glycation end-products (AGEs) and their receptor (RAGE) play an important role in the
pathogenesis of diabetic vascular complications. Recently, soluble form of RAGE (sRAGE) has been identiﬁed in
mice and humans. Statins have been reported to increase serum sRAGE levels. However, whether modulation
of circulating sRAGE levels has a beneﬁcial effect on the progression of atherosclerosis is unknown.
Methods:We reviewed 91 patients who had undergone percutaneous coronary intervention for angina pectoris.
Coronary atherosclerosis in non-culprit lesions in the target vessel was evaluated, using virtual histology intra-
vascular ultrasound, and serum levels of AGEs and sRAGEweremeasured, at baseline and after 8 months of statin
therapy.
Results: Statins had no effects on serum AGEs levels; however, serum levels of sRAGEwere signiﬁcantly higher at
the 8-month follow-up. A signiﬁcant decrease in external elastic membrane (EEM) volume (−1.6%, p = 0.005)
was observed, whereas a decrease in plaque volume did not reach statistical signiﬁcance (−1.9%, p = 0.16).
Univariate regression analyses showed that the percentage changes in serum sRAGE were negatively correlated
with those in EEM volume (r =−0.198, p = 0.06) and plaque volume (r =−0.247, p = 0.02). Multivariate
regression analysis showed that an increase in serum sRAGE level was an independent predictor of atheroma
regression after statin therapy (β=−0.290, p = 0.006).
Conclusions: Statin therapy increased serum sRAGE levels, and this increase was associated with negative vessel
remodeling and atheroma regression in the coronary artery.
© 2014 The Authors. PublishedbyElsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).partment of Internal Medicine,
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Advanced glycation end-products (AGEs) and their receptor (RAGE)
play an important role in the pathogenesis of diabetic vascular compli-
cations [1–3]. Recently, soluble form of RAGE (sRAGE) has been identi-
ﬁed in mice and humans [4]. Administration of a recombinant sRAGE
has been shown to suppress the development of atherosclerosis asunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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(apo) E-null mice [5,6]. These observations suggest that sRAGE acts as
a decoy receptor for AGEs. However, since AGEs up-regulate RAGE
expression levels in various tissues and that sRAGE could be mainly
generated from proteolytic cleavage of membrane-bound RAGE by
the actions of sheddase, a disintegrins and metalloproteinases 10
(ADMA 10) [4,7,8], it is also possible that sRAGE may reﬂect tissue
RAGE expression and the severity of target organ damage. Accordingly,
whether sRAGE is a biomarker that could reﬂect tissue damage or a pro-
tective one against injury might differ considerably depending on the
patients' background. Indeed, although Falcone et al. reported that low
levels of sRAGE were independently associated with the presence
of coronary artery disease in non-diabetic men [9], prospective studies
have shown that higher levels of sRAGE are associated with incident
of cardiovascular disease or all-cause mortality in subjects with either
type of diabetes [10–12].
The beneﬁcial effects of statin therapy in reducing cardiovascular
pathogenesis, atherosclerosis, and diabetic complications are well
known. Although the mechanisms by which statins provide cardiovas-
cular beneﬁts are not fully understood, the regression and stabilization
of coronary artery plaque are presumed to play an important role
in this effect [13,14]. A recent study has reported that statins stimulate
the production of sRAGE [15]. Although atorvastatin has been shown
to increase serum sRAGE levels [16], whether modulation of circulating
sRAGE levels has a beneﬁcial effect on the progression of atherosclero-
sis is unknown. In this study, we examined the effects of statins on
serum AGEs and sRAGE levels and their association with coronary
atherosclerosis.
2. Methods
2.1. Patients and study design
The present study is a post-hoc subanalysis of the Treatment With
Statin on Atheroma Regression Evaluated by Intravascular Ultrasound
With Virtual Histology (TRUTH) trial. The TRUTH study was a pro-
spective, open-label, randomized, multicenter trial performed at 11
Japanese centers to evaluate the effects of 8 months' treatment with
pitavastatin versus pravastatin on coronary atherosclerosis using virtual
histology (VH)-intravascular ultrasound (IVUS) [17]. Brieﬂy, 164 pa-
tients with angina pectoris were randomized to either pitavastatin
(4 mg/day, intensive lipid-lowering) or pravastatin (20 mg/day, mod-
erate lipid-lowering) therapy after successful percutaneous coronary
intervention (PCI) performed under VH-IVUS guidance. None of the
participants were taking a statin or other lipid-lowering drugs at the
timeof study enrollment. A follow-up IVUS examinationwas performed
after 8 months of statin therapy.
The inclusion criteria of this study were analyzable IVUS data
obtained at PCI and at the 8-month follow-up, along with adequate
serum volume in frozen samples for various measurements. A total of
91 patients were included in this study.
The TRUTH studywas conducted in accordancewith the Declaration
of Helsinki and with the approval of the ethical committees of the 11
participating institutions. Each patient enrolled in the study provided
written informed consent.
2.2. IVUS examination and analysis
The details of the IVUS procedure have been documented elsewhere
[17]. Brieﬂy, after PCI of the culprit lesion, IVUS examination was per-
formed on angiographic lesionswithout signiﬁcant stenosis by coronary
angiogram (diameter stenosis b 50%). An IVUS catheter (Eagle Eye Gold;
Volcano Corporation, San Diego, California) was used, and a motorized
pullback device was used to withdraw the transducer at 0.5 mm/s.
During pullback, grayscale IVUS was recorded, and raw radiofrequency
data were captured at the top of the R wave using a commerciallyavailable IVUS console (IVG3; Volcano Corporation). After 8 months of
statin therapy, the IVUS examinationwas repeated in the same coronary
artery, using the same type of IVUS catheter that was used at baseline.
All baseline and follow-up IVUS core laboratory analyses were
performed by an independent and experienced investigator (M.T.) in
a blinded manner. Before IVUS analysis, baseline and follow-up IVUS
images were reviewed side-by-side on a display, and the distal and
proximal ends of the target segmentwere identiﬁed based on reproduc-
ible anatomical landmarks such as the side branch, vein, and stent edge.
Plaques close to the PCI site (b5 mm) were excluded because mechan-
ical interventions affected atheroma measurements. Quantitative IVUS
grayscale analysis was performed according to the guidelines of the
American College of Cardiology and European Society of Cardiology
[18]. Manual contour detection of the lumen and external elastic
membrane (EEM) was performed for each frame. The EEM volume
and lumen volume were calculated, and the difference between the 2
values was deﬁned as plaque volume. All volumetric data were divided
by lesion length to obtain a volume index. Intraobserver analysis was
carried out in 25 randomly selected lesions from 25 vessels at least
4 weeks apart. The intraobserver variabilities for the EEM volume and
lumen volume were 2.5 ± 2.4% and 2.7 ± 2.5%, respectively. VH-IVUS
data analysis was based on calculation of grayscale border contour,
and the relative and absolute quantities of different coronary artery
plaque componentsweremeasured using IVUSLab version 2.2 (Volcano
Corporation). Fibrous tissue was marked in green, ﬁbro-fatty in yellow,
dense calcium in white, and necrotic core in red on the VH-IVUS
image [19].
2.3. Blood sampling and measurement of blood parameters
Blood samples were obtained after an overnight fast at baseline and
at the 8-month follow-up. The levels of serum lipid and high-sensitivity
C-reactive protein (hs-CRP)weremeasured at a central clinical laborato-
ry (SRL Inc., Tokyo). Serum levels of total cholesterol, low-density lipo-
protein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol,
and triglycerides were measured by standard enzymatic methods.
Serum oxidized LDL levels weremeasured by an enzyme immunoassay.
Serum levels of small dense LDL, AGEs, and sRAGEweremeasured using
conserved frozen samples. Serumsmall dense LDL levelsweremeasured
by a homogeneous assay (Denka Seiken Co., Ltd., Tokyo) [20]. Serum
AGEs levels were measured by enzyme-linked immunosorbent assay
(ELISA), as described previously [21]. sRAGE levels were determined
using a commercially available ELISA kit (R&D systems, Minneapolis,
Minnesota).
2.4. Statistical analysis
Statistical analysis was performed using StatView version 5.0 (SAS
Institute, Cary, North Carolina). Results are expressed as mean ± SD
or as median (range). Differences in continuous variables were com-
pared using Student's paired t tests when variables showed a normal
distribution, and the Wilcoxon signed rank-sum test when the vari-
ables were not normally distributed. Univariate and multivariate
regression analyses were performed to assess predictors associated
with percentage changes in EEM volume and plaque volume after
statin therapy. The variables with a p value b 0.2 on univariate analysis
were entered into multivariate models. Statistical signiﬁcance was set
at p b 0.05.
3. Results
3.1. Patients' characteristics and laboratory results
Thepatients' baseline characteristics are listed in Table 1. Theirmean
age was 67 years, and 75 patients (82%) were men. Sixty-six patients
(73%) had stable angina pectoris, and the remaining 25 (27%) had
Table 1
Baseline characteristics of subjects.
All subjects
(n = 91)
Age (years) 67 ± 10
Men 75 (82%)
Body mass index (kg/m2) 24.2 ± 3.4
eGFR (ml/min/1.73 m2) 64.4 ± 14.4
Status of coronary artery disease
Stable angina pectoris 66 (73%)
Unstable angina pectoris 25 (27%)
Treatment allocation
Pitavastatin 46 (51%)
Pravastatin 45 (49%)
Target coronary artery
Left anterior descending 51 (56%)
Left circumﬂex 4 (4%)
Right 36 (40%)
Type of stent
Bare metal stent 15 (16%)
Drug-eluting stent 76 (84%)
Hypertension 60 (66%)
Diabetes mellitus 41 (45%)
Smoking 22 (24%)
Medications
ACE inhibitors or ARBs 49 (54%)
Beta-blockers 9 (10%)
Calcium channel blockers 50 (55%)
Data are expressed as the mean ± SD or number (%).
eGFR, estimated glomerular ﬁltration rate; ACE, angiotensin-converting enzyme; and
ARBs, angiotensin-receptor blockers.
Table 3
The parameters evaluated using grayscale IVUS and VH-IVUS at baseline and at the
8-month follow-up.
Baseline Follow-up p value
EEM volume index (mm3/mm) 15.94 ± 4.78 15.66 ± 4.75 0.005
% change −1.6 ± 5.7
Plaque volume index (mm3/mm) 8.65 ± 2.60 8.53 ± 2.60 0.16
% change −1.9 ± 10.5
Lumen volume index (mm3/mm) 7.30 ± 2.66 7.13 ± 2.60 0.07
% change −1.6 ± 11.8
PAV (%) 54.5 ± 6.4 54.7 ± 6.4 0.65
Nominal change (%) 0.2 ± 4.2
FI volume index (mm3/mm) 3.16 ± 1.47 3.08 ± 1.37 0.32
Change (mm3/mm) −0.08 ± 0.78
FF volume index (mm3/mm) 1.03 ± 0.76 0.75 ± 0.60 b0.0001
Change (mm3/mm) −0.28 ± 0.58
NC volume index (mm3/mm) 0.71 ± 0.52 0.85 ± 0.53 0.02
Change (mm3/mm) 0.14 ± 0.54
DC volume index (mm3/mm) 0.39 ± 0.32 0.49 ± 0.36 b0.0001
Change (mm3/mm) 0.14 ± 0.54
Average length (mm) 25 ± 15 25 ± 15 0.67
Data are expressed as the mean ± SD.
EEM, external elastic membrane; PAV, percent atheroma volume; FI, ﬁbrous; FF, ﬁbro-
fatty; NC, necrotic core; and DC, dense calcium.
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pitavastatin, and the remaining 45 (49%) received pravastatin.
Risk factor data at baseline and at the 8-month follow-up are shown
in Table 2. At the 8-month follow-up, serum levels of total cholesterol,
LDL cholesterol, triglycerides, apolipoprotein B, hs-CRP, and small
dense LDL had decreased signiﬁcantly, whereas serum levels of HDL
cholesterol and apolipoprotein A1 had increased signiﬁcantly. Statins
had no effects on serum AGEs levels; however, serum levels of sRAGE
were signiﬁcantly higher at the 8-month follow-up.
3.2. Grayscale IVUS and VH-IVUS analysis
The parameters evaluated using grayscale IVUS and VH-IVUS
are listed in Table 3. A signiﬁcant decrease in EEM volume (−1.6%,
p = 0.005) was observed, whereas a decrease in plaque volume did
not reach statistical signiﬁcance (−1.9%, p = 0.16). A signiﬁcantTable 2
Risk factor control at baseline and at the 8-month follow-up.
Baseline Follow-up p value
Total cholesterol (mg/dl) 203 ± 35 158 ± 27 b0.0001
LDL cholesterol (mg/dl) 130 ± 32 84 ± 25 b0.0001
Triglycerides (mg/dl) 116 (36 to 573) 102 (37 to 360) 0.005
HDL cholesterol (mg/dl) 47 ± 11 51 ± 13 0.0004
Apolipoprotein A1 (mg/dl) 118 ± 20 132 ± 26 b0.0001
Apolipoprotein B (mg/dl) 104 ± 24 74 ± 17 b0.0001
Hs-CRP (ng/ml) 4100 (54 to 88900) 642 (52 to 26200) b0.0001
Oxidized LDL (U/ml) 12 ± 9 11 ± 9 0.19
Lipoprotein(a) (mg/dl) 16 (1 to 47) 14 (1 to 118) 0.002
Small dense LDL (mg/dl) 26 ± 14 19 ± 9 b0.0001
Glucose (mg/dl) 112 ± 33 108 ± 33 0.046
HbA1c (%) 6.3 ± 1.0 6.2 ± 0.8 0.26
AGEs (U/ml) 11.6 ± 5.7 11.5 ± 4.0 0.93
sRAGE (pg/ml) 974 ± 425 1041 ± 434 0.049
Data are expressed as the mean ± SD or as median (range).
LDL, low-density lipoprotein; HDL, high-density lipoprotein; hs-CRP, high-sensitivity
C-reactive protein; HbA1c, hemoglobin A1c; AGEs, advanced glycation end-products;
and sRAGE, soluble form of receptor for AGEs.decrease in the ﬁbro-fatty component (−0.28 mm3/mm, p b 0.0001)
and increases in the necrotic core (0.14 mm3/mm, p = 0.02) and
dense calcium components (0.14 mm3/mm, p b 0.0001) were observed
after 8 months' statin therapy.
3.3. Predictors of percentage change in plaque volume after statin therapy
Univariate regression analyses showed that the percentage change in
serum sRAGE was negatively correlated with the percentage changes in
EEM volume (r =−0.198, p = 0.06) and plaque volume (r =−0.247,
p = 0.02) (Fig. 1). Age tended to be positively correlated with the per-
centage change in plaque volume on univariate regression analysis
(Table 4). Multivariate regression analysis showed that an increase
in serum sRAGE was an independent negative predictor (β=−0.290,
p = 0.006), and age was an independent positive predictor (β= 0.222,
p = 0.03) associated with atheroma progression after statin therapy.
An increase in serum sRAGE levels did not correlate with the changes in
any of the 4 plaque components evaluated by VH-IVUS.
4. Discussion
The major ﬁndings of this study are as follows: (1) serum sRAGE
levels were elevated after statin therapy following PCI, (2) this increase
in serum sRAGE levels was associated with negative vessel remodeling
and a regression in plaque volume, butwas not correlated with changes
in plaque composition; and (3) an increase in serum sRAGE was an in-
dependent predictor associated with atheroma regression after statin
therapy.
Serum levels of sRAGE are positively rather than inversely correlated
with circulating AGEs in both diabetic and non-diabetic subjects [4]. In
addition, serumsRAGE levels are signiﬁcantly higher in diabetic patients
than in non-diabetic subjects [22]. Furthermore, serum sRAGE levels
were one of the independent determinants of coronary artery disease
in patients with diabetes [22]. On the basis of these reports, serum
sRAGE levels may reﬂect tissue RAGE expression and may be elevated
as a compensatory mechanism against AGE-elicited tissue damage and
circulating sRAGE level is a novel biomarker of vascular inﬂammation
in diabetic patients. However, Falcone et al. reported that low levels
of sRAGE were independently associated with the presence of coro-
nary artery disease in non-diabetic men [9]. In addition, Selvin et al.
reported that low plasma levels of sRAGE were independently associ-
ated with the risk of cardiovascular disease and all-cause mortality in
community-based population [23]. These observations suggest that
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Fig. 1. Correlations between percentage change in serum soluble form of receptor for advanced glycation end products (sRAGE) and percentage change in external elastic mem-
brane (EEM) volume (a) or plaque volume (b) during statin therapy. The percentage change in serum sRAGE was negatively correlated with the percentage changes in EEM volume
(r =−0.198, p = 0.06) and plaque volume (r =−0.247, p = 0.02) after statin therapy.
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depending on the patient's background, particularly with or without
diabetes [24].
A few studies have evaluated the effect of pharmacotherapies on
serum sRAGE levels and there is still some controversy over the thera-
peutic modulation of sRAGE. Forbes et al. reported that inhibition of the
renin–angiotensin system by perindopril, an angiotensin-converting en-
zyme inhibitor, in patients with type 1 diabetes increased plasma sRAGE
levels [25]. Nakamura et al. reported that telmisartan, an angiotensin re-
ceptor blocker, decreased serum sRAGE levels in patients with essential
hypertension [26]. A recent ex-vivo study reported that statin stimulates
the production of sRAGE [15]. In addition, atorvastatin increased serumTable 4
Predictors of the percentage change in plaque volume after statin therapy.
Univariate Multivariate
r p value β p value
Age 0.166 0.12 0.222 0.03
Gender −0.057 0.59
Coronary artery disease status −0.024 0.82
Hypertension 0.106 0.32
Diabetes mellitus 0.133 0.21
Smoking 0.104 0.32
Type of statin −0.051 0.63
Total cholesterol (% change) −0.025 0.81
LDL cholesterol (% change) −0.025 0.81
Triglycerides (% change) 0.061 0.57
HDL cholesterol (% change) −0.107 0.31
Apolipoprotein A1 (% change) −0.098 0.35
Apolipoprotein B (% change) 0.012 0.91
Hs-CRP (% change) 0.087 0.42
Oxidized LDL (% change) 0.094 0.39
Lipoprotein(a) (% change) 0.020 0.85
Small dense LDL (% change) −0.040 0.71
Glucose (% change) −0.026 0.83
HbA1c (% change) −0.189 0.26
AGEs (% change) −0.063 0.55
sRAGE (% change) −0.247 0.02 −0.290 0.006
Male gender, unstable angina pectoris, hypertension, diabetes mellitus, smoking,
and pitavastatin were assigned a value of 1. Female gender, stable angina pectoris,
normotension, non-smoking, non-diabetes mellitus, and pravastatin were assigned a
value of 0.sRAGE levels [16,27]. Consistently with these reports, in the present
study, statin therapy was associated with an increase in serum sRAGE
levels. In addition, an increase in serum sRAGE was associated with
negative vessel remodeling and atheroma regression in the coronary
artery. To the best of our knowledge, this is the ﬁrst report to evaluate
the effect of statins on serum sRAGE levels and its association with
changes in coronary atherosclerosis.
RAGE is up-regulated in the atherosclerotic plaque in patients with
diabetes [28]. In addition, recent studies reported that statin therapy
attenuates the accumulation of RAGE in plaque [29,30]. Although we
did not evaluate the RAGE expression in plaque, its inhibition following
statin therapy could play a role in negative vessel remodeling and ather-
oma regression in the coronary arteries. Statin therapy decreasesmatrix
metalloproteinase (MMP) activity and increases collagen content in
human plaques [31,32], while circulating MMP levels are associated
with coronary artery plaque regression [33]. Recently, Cuccurullo et al.
reported that RAGE suppression by simvastatin had a protective impact
on plaque phenotype, while reduced MMP expression was correlated
with an increase in plaque collagen content after statin therapy [30].
These reports suggest that statin therapy stabilizes coronary artery
plaques via the suppression of RAGE and MMP expression within the
atherosclerotic plaque.
The beneﬁcial effects of statin therapy in reducing cardiovascular
pathogenesis, atherosclerosis, and diabetic complications are well
known. Of course, these effects of statins aremainly based on the reduc-
tion of LDL cholesterol levels. However, the clinical beneﬁts of statins
are greater than those expected from their LDL cholesterol-lowering
effect alone. Statins are known to have pleiotropic effects, which include
reducing CRP and AGEs [34,35]. RAGE is the best known target for AGEs
in the vasculature, and it is well established that the AGEs–RAGE system
contributes to the progression of atherosclerotic plaque in animal
models [6,36,37]. Previous studies reported that atorvastatin decreased
serum levels of AGEs in patients with type 2 diabetes or nonalcoholic
steatohepatitis, or non-diabetic patients with chronic kidney disease
[35,38,39]. However, we did not observe a decrease in serum AGEs
levels after statin therapy. sRAGE level is independently and inversely
associated with high mobility group box 1 (HMGB1) value in a general
population [40]. HMGB1 is one of the ligands for RAGE, and HMGB1 and
RAGE interaction promotes chemotaxis and maturation of immune
cells, enhances the expression of adhesion molecules, and stimulates
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increased in diabetic RAGE−/−/apoE−/−mice, while sRAGE is absent in
these animals [40]. Furthermore, HMGB1 has 10 times higher binding
afﬁnity to RAGE, and its serum concentration is 1000 times less than
that of AGEs [4,40]. These ﬁndings suggest that circulating HMGB1 but
not AGEs might be a molecular target for sRAGE. An increase in sRAGE
levels observed in this study is one of the pleiotropic effects of statins,
as previously reported [16,27]. Given the correlations between the in-
crease in serum sRAGE levels and plaque regression or negative vessel
remodeling after statin therapy, statin-induced changes in coronary
atherosclerosis may be mediated, in part, by the AGEs-RAGE system.
4.1. Limitations
Our study has several limitations. First, although sRAGE may be an
important targetmolecule for preventing the progression of atheroscle-
rosis, this study was a post-hoc subanalysis. In addition, serum sRAGE
levels were measured using frozen samples, and we cannot clarify the
source of elevated serum sRAGE levels. Furthermore, we neither evalu-
ated the RAGE and MMP expression in plaques nor measured serum
MMP and HMGB1 levels. Second, although we excluded patients with
angiographically apparent thrombi, an intramural thrombus might
have inﬂuenced the study results. Third, the IVUS examination was
only performed in non-culprit lesions in the culprit vessel. Mechanical
interventions might have affected the atheroma measurement. Finally,
this study was limited by the relatively small number of patients
and had no control subjects who did not take statins during the
8 months following PCI. Larger prospective studies are necessary to
conﬁrm the role of sRAGE in the progression or regression of coronary
atherosclerosis.
5. Conclusions
Statin therapy after PCI increased serum sRAGE levels and this in-
crease was associated with negative vessel remodeling and atheroma
regression in the target coronary artery. Statin-induced changes in
coronary atherosclerosis may be mediated, in part, by the AGEs-RAGE
system.
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